SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

23 Jan 2024 Evaluate
The revenue zoomed 12.65% to Rs. 4490.50 millions for the quarter ended December 2023 as compared to Rs. 3986.40 millions during the corresponding quarter last year.The Company's Net profit for the December 2023 quarter have declined marginally to Rs. 200.10  millions as against Rs. 278.70 millions reported during the corresponding quarter ended.Operating Profit saw a handsome growth to 682.20 millions from 620.20 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 4490.50 3986.40 12.65 13453.20 12392.30 8.56 16666.90 15397.20 8.25
Other Income 29.30 3.70 691.89 44.60 18.40 142.39 23.30 23.20 0.43
PBIDT 682.20 620.20 10.00 2050.80 2225.50 -7.85 2872.20 3293.20 -12.78
Interest 100.30 70.10 43.08 259.10 163.90 58.08 250.30 141.40 77.02
PBDT 499.90 550.10 -9.13 1709.70 2061.60 -17.07 2621.90 3151.80 -16.81
Depreciation 229.70 171.60 33.86 642.50 529.10 21.43 706.00 789.50 -10.58
PBT 270.20 378.50 -28.61 1067.20 1532.50 -30.36 1915.90 2362.30 -18.90
TAX 70.10 99.80 -29.76 276.30 372.70 -25.87 502.30 817.10 -38.53
Deferred Tax 47.70 17.70 169.49 53.30 -55.80 -195.52 -49.70 -73.40 -32.29
PAT 200.10 278.70 -28.20 790.90 1159.80 -31.81 1413.60 1545.20 -8.52
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 15.19 15.56 -2.35 15.24 17.96 -15.12 17.23 21.39 -19.43

Indoco Remedies Share Price

227.95 12.10 (5.61%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×